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The Diabetes Subgroup Baseline Characteristics of the Avoiding
Cardiovascular Events Through Combination Therapy in
Patients Living With Systolic Hypertension (ACCOMPLISH)
Trial
Diabetes mellitus (DM) is the mostcommon cause of kidney failure
and a major cause of cardiovascular
morbidity and mortality.1 The Avoid-
ing Cardiovascular Events Through
Combination Therapy in Patients
Living With Systolic Hypertension
(ACCOMPLISH) trial examined
cardiovascular outcomes in approxi-
mately 12,000 patients, many of whom
have DM. A full description of the base-
line data for the entire ACCOMPLISH
trial as well as the methods and design
of this trial have been published
previously.2,3
Briefly, ACCOMPLISH is a ran-
domized double-blind trial that com-
pared the efficacy of one fixed-dose
combination, amlodipine besylate/
benazepril, to that of another, benazep-
ril/hydrochlorothiazide, in preventing
fatal and nonfatal cardiovascular out-
comes.2 Patients randomized to study
medications did not have a washout
period. The study drug doses were
force-titrated during the first 2 months
of the trial to maximum angiotensin-
converting enzyme inhibitor levels:
amlodipine besylate/benazepril 5/40
mg and benazepril/ hydrochlorothia-
zide 40/12.5 mg. Within the first 3
months, dose increases to 10/40 mg or
40/25 mg, respectively, could occur to
achieve blood pressure (BP) goals. If
BP was still not at goal level, addition
of other antihypertensive agents with
the exception of the randomized drug
classes could occur. These additional
antihypertensive agents included
b-blockers, a-blockers, and clonidine,
and, if needed, loop diuretics could be
added in order to reach BP targets
(<140/90 mm Hg for most patients
and <130/80 mm Hg [suggested, but
not mandated] for patients with DM
or renal insufficiency). After the initial
3-month period, patients were seen at
6-month intervals thereafter until the
end of the 5-year trial.
ACCOMPLISH is distinctly differ-
ent from previously completed cardio-
vascular outcomes trials in that it was
designed to not have differences in BP
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within the first 6 to 12 months of the
study. Previous trials like the Valsar-
tan Antihypertensive Long-Term Use
Evaluation (VALUE), the Anglo-Scan-
dinavian Cardiac Outcomes Trial
(ASCOT), and the Antihypertensive
and Lipid-Lowering Treatment to Pre-
vent Heart Attack Trial (ALLHAT)4–6
all had significant differences in BP
within the first year of the trial, which
affected the event rate early in
VALUE.7
The data in this report represent
those of the cohort with DM and are
based on all available BP observations
at baseline (the beginning of the
study treatment period immediately
following randomization) and at 6
months. As of this writing, 11, 464
patients had BP data available for the
present analysis. There is no discussion
about the primary and other mortality/
morbidity end points in this report.
Results
Patient Characteristics. The inclu-
sion and exclusion criteria for hyper-
tensive patients at high cardiovascular
risk have been described previously.2,3
The baseline demographic distribution
of patients with DM is shown in
Table I. Note that the cohort with
DM in this trial had fewer cardiovascu-
lar events at entry compared with other
clinical trials. The distribution of
patients with DM between the United
States and Scandinavia is shown in
Table II. The distributions of cardio-
vascular events prior to randomization
differed between those with and with-
out DM, favoring fewer events in the
DM cohort (Figure 1).
The previous antihypertensive medi-
cation history of the cohort is shown in
Table III. Note that 4% of those with
DM had nephropathy defined by either
the presence of macroalbuminuria (uri-
nary albumin excretion >300 mg/d) or
an estimated glomerular filtration rate
<60 mL/min.
The baseline values for standard lab-
oratory blood test results were similar in
both the DM and non-DM cohorts,
with the exception of values of fasting
glucose and triglycerides and rates of
albuminuria and microalbuminuria,
which were all higher in DM patients
(Table IV).
Effects of Initial Combination
Therapy on BP. Baseline values of BP
were measured before the initiation of
study drugs, while patients were still
receiving prestudy medications. Baseline
BP values were similar across most sub-
groups, with the exception of the partici-
pants enrolled at the Nordic sites, where
systolic BP values at the time of random-
ization were approximately 10 mm Hg
higher than in patients from the United
States. The higher baseline BP level in
the Nordic countries was due to local
regulatory advice to only include patients
in the trial whose BP was not controlled
on their prestudy medications. In con-
trast, the United States investigators






Male, % 57.3 66.0
Female, % 42.7 34.0
Mean age, y 67.5 69.8
Mean weight, kg 91.8 83.7
Mean height, cm 168.8 169.8






Table II. Distribution of Patients With






Denmark (n=532) 37.6 62.4
Finland (n=587) 62.5 37.5
Norway (n=293) 34.9 65.1




Total (N=11,464) 60.7 39.3
Figure 1. Baseline cardiovascular history comparing the cohorts with (DM) and without
(non-DM) diabetes mellitus. LVH indicates left ventricular hypertrophy; PAD, peripheral arter-
ial disease; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous
coronary intervention.
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could enroll patients with either well-
controlled or uncontrolled BP.
The mean BP for DM patients at
study entry was 145.2/79.3 mm Hg. It
was similar to those in the non-DM
cohort: 145.4/80.0 mm Hg. At base-
line, only 16% of DM patients had
baseline BP values below the recom-
mended goal level of <130/80 mm Hg
(Figure 2). The effects of treatment on
systolic BP after 6 months are shown in
Figure 2.
Maximum Dose Plus Additional
Antihypertensive Therapy. The study
design required forced titration of the
study drug to achieve BP goals; if goal
levels were not achieved, add-on ther-
apy with the aforementioned agents
should be started. At 6 months, similar
numbers of the cohort with and without
DM were receiving maximally titrated
doses of study medication (30.3% of
the DM cohort vs 29.4% of the non-
DM cohort). However, the number of
patients requiring add-on medications
differed: 16.9% in the DM group vs
10.6% in the non-DM group required
1 additional medication. Note that
8.9% of the DM cohort vs only 4.3% of
the non-DM cohort required >2 addi-
tional antihypertensive medications to
achieve BP goals in addition to maxi-
mally dosed study agents. The distribu-
tion of this add-on therapy by drug class
is shown in Figure 3.
Discussion
ACCOMPLISH is the first trial to ran-
domize 2 different fixed-dose combina-
tions in a high-risk cohort to assess
cardiovascular outcomes. The recom-
mendation to initiate combination
therapy in persons with stage 2 hyper-
tension and in those with BP levels
20/10 mm Hg above the their goal
value was clear in the Seventh Report of
the Joint National Committee on
Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure
(JNC 7).8 Thus, anyone who has DM
and a BP of 150/90 mm Hg should
be started on 2 antihypertensive medi-
cations, 1 of which included a thiazide-
like diuretic based on these guidelines.
The DM cohort in the largest trial to
date, ALLHAT, found that diuretic
treatment should be included as a
part of the initial therapy for BP.9
ACCOMPLISH will provide further
information in a different setting (ie,
pairing a thiazide diuretic with a blocker
of the renin-angiotensin system) as to
whether this should be the case to
reduce cardiovascular outcomes. While
both trials have a large group of patients
with DM, one major difference is that
achievement of a BP goal of <130/80
mm Hg occurred much earlier (at 6
months) in the ACCOMPLISH trial
compared to in ALLHAT, where it took
much longer.6,9 This difference in total
BP load may yield ultimately different
cardiovascular outcomes. This was cer-
tainly the case in VALUE.7 This trial,
along with the early large differences in
BP values between groups receiving
monotherapy in ALLHAT and
ASCOT, may have also contributed to
differences in those trial outcomes.
It is known that those with predom-
inant systolic hypertension, such as the
elderly, as well as those with DM are
more likely to require a higher number
of antihypertensive medications to
achieve BP goals.10 The Intervention as
a Goal in Hypertension Treatment
(INSIGHT) trial in elderly individuals
with predominant systolic hyper-
tension mandated a relatively higher





No drug therapy 0.5 0.9
ACE inhibitors 56.7 46.1
CCBs 35.9 37.8
ARBs 28.1 23.1
Thiazide/thiazide-like diuretics 38.7 35.2
Aldosterone receptor blockers 1.6 1.4
b-Blockers 40.6 58.1
a-Blockers 8.4 7.9
Loop diuretics 13.9 10.0
Clonidine or clonidine-like agents 3.2 2.5
Oral hypoglycemics and insulin sensitizers 65.0 0.2
Insulin 21.7 0
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
CCB, calcium channel blocker; DM, diabetes mellitus. Values are expressed
as percentages.






Fasting plasma glucose, mg/dL 144.5 101
Lipids
Total cholesterol, mg/dL 184.6 184
HDL cholesterol, mg/dL 48.3 51.4
LDL cholesterol, mg/dL 101.1 102.4
Triglycerides, mg/dL 178 149.7
Kidney function
eGFR, mL/min/1.73 m2 80.4 76.3





albumin excretion 30–300 mg/dL)
29.3 20.3
Abbreviations: DM, diabetes mellitus; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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number of antihypertensive medica-
tions in the cohort with DM to achieve
BP goals.11 In ACCOMPLISH, our
cohort with DM did not have predom-
inant systolic hypertension but did
require a higher number of antihyper-
tensive medications compared with the
nondiabetic cohort to achieve the BP
goal.
The hope is that ACCOMPLISH,
with its initial treatment using fixed-
dose combination therapy, will not
result in this large early BP differen-
tial and thus will provide a better
representation as to whether diuretics
should be agents used early in the paired
therapies to treat persons with DM.
Better BP control in ACCOMPLISH
is evinced by the fact that the BP goal of
<130/80 mm Hg was reached in
>43% of patients with DM within the
first 6 months of the trial. Moreover,
the BP goal of <140/90 mm Hg was
achieved in >72% by this time, a far
better percentage than in any previous
clinical trial.12
More than half of the randomized
patients in the ACCOMPLISH trial
had DM at study entry. In comparison
to the non-DM patients, DM patients
were more likely to be overweight,
female, and black. More DM patients
than non-DM patients had kidney dis-
ease and higher triglyceride levels and
were previously treated with an angio-
tensin-converting enzyme inhibitor or
an angiotensin receptor blocker. While
there were similar levels of baseline BP
present between the DM and non-DM
cohort, only 16% of DM patients had
BP that was at the recommended goal at
study entry (<130/80 mm Hg). This
percentage improved to 43% following
6 months of participation in the trial.
Moreover, a higher percentage of DM
patients required add-on therapy in
addition to the maximum dosage of
study drugs to achieve the goal BP.
These early data in the cohort with
DM in ACCOMPLISH indicate that
BP control has been achieved to a
greater extent than in any other previous
trial, as would have been anticipated
from earlier studies comparing initial
monotherapy to combination therapy
in patients with DM.13 Data from the
ACCOMPLISH trial on BP control
will provide new insights as to how to
approach this growing segment of the
population and further lower their
cardiovascular risk.
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